Citius Pharmaceuticals
CTXR
73 hedge funds and large institutions have $24.2M invested in Citius Pharmaceuticals in 2024 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 19 increasing their positions, 22 reducing their positions, and 11 closing their positions.
18% more capital invested
Capital invested by funds: $20.5M → $24.2M (+$3.75M)
0% less ownership
Funds ownership: 0.68% → 0.68% (-0%)
9% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 11
1% less funds holding
Funds holding: 74 → 73 (-1)
14% less repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 22
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$196K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$121K |
| 3 |
WAS
Wealth Advisory Solutions
Indiianapolis,
Indiana
|
+$110K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$76.6K |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$54.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$216K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$94.8K |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$93.8K |
| 4 |
Barclays
London,
United Kingdom
|
-$54.3K |
| 5 |
VF
Virtu Financial
New York
|
-$39K |
CTXR Hedge Fund Activity: Q1 2024 in Review
73 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Citius Pharmaceuticals (CTXR) for Q1 2024, worth a combined $24.2M — up 18% from $20.5M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of CTXR and 10 opened new positions — a net loss of 1 holder — while 22 trimmed existing stakes and 19 added.
The largest buyer was BlackRock, adding an estimated $196K. The largest seller was Morgan Stanley, cutting an estimated $216K.
- 73 institutional investors held Citius Pharmaceuticals (CTXR) as of Q1 2024, down from 74 in Q4 2023.
- Funds reported $24.2M of Citius Pharmaceuticals stock for Q1 2024, up 18% quarter-over-quarter.
- 10 funds opened new Citius Pharmaceuticals positions in Q1 2024 and 11 closed out, a net change of -1 holder.
- The largest Citius Pharmaceuticals buyer in Q1 2024 was BlackRock, an estimated $196K added.
- The largest Citius Pharmaceuticals seller in Q1 2024 was Morgan Stanley, an estimated $216K sold.
Based on aggregated 13F filings for Q1 2024.